Zacks Research Has Pessimistic Outlook of Clorox Q2 Earnings

The Clorox Company (NYSE:CLX - Free Report) - Investment analysts at Zacks Research reduced their Q2 2025 earnings estimates for Clorox in a research report issued to clients and investors on Wednesday, November 13th. Zacks Research analyst R. Lohia now expects that the company will earn $1.39 per share for the quarter, down from their prior estimate of $1.56. The consensus estimate for Clorox's current full-year earnings is $6.85 per share. Zacks Research also issued estimates for Clorox's Q3 2025 earnings at $1.68 EPS, Q4 2025 earnings at $1.92 EPS, FY2025 earnings at $6.85 EPS, Q2 2026 earnings at $1.69 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at $1.90 EPS, FY2026 earnings at $7.17 EPS, Q1 2027 earnings at $1.81 EPS and FY2027 earnings at $7.56 EPS.

A number of other research firms also recently commented on CLX. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Clorox from $144.00 to $151.00 and gave the stock a "hold" rating in a report on Friday, August 2nd. Evercore ISI dropped their price objective on shares of Clorox from $140.00 to $139.00 and set an "underperform" rating on the stock in a research note on Monday, October 14th. TD Cowen upgraded shares of Clorox from a "sell" rating to a "hold" rating and raised their price target for the company from $155.00 to $170.00 in a report on Wednesday, November 6th. Citigroup increased their price target on Clorox from $165.00 to $170.00 and gave the company a "neutral" rating in a report on Friday, September 6th. Finally, JPMorgan Chase & Co. boosted their price objective on Clorox from $148.00 to $174.00 and gave the stock a "neutral" rating in a research report on Friday, October 11th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, Clorox presently has a consensus rating of "Hold" and an average target price of $155.00.

Clorox Price Performance

CLX traded up $2.05 on Friday, reaching $167.80. The company had a trading volume of 672,457 shares, compared to its average volume of 1,239,273. The company has a fifty day moving average of $162.39 and a 200-day moving average of $147.34. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. The company has a market capitalization of $20.77 billion, a P/E ratio of 58.07, a PEG ratio of 3.06 and a beta of 0.41. Clorox has a one year low of $127.60 and a one year high of $169.09.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.36 by $0.50. The firm had revenue of $1.76 billion for the quarter, compared to analysts' expectations of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. Clorox's revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company posted $0.49 earnings per share.

Clorox Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd were issued a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date was Wednesday, October 23rd. Clorox's dividend payout ratio is currently 170.04%.

Insiders Place Their Bets

In other news, EVP Angela C. Hilt sold 1,733 shares of the company's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the transaction, the executive vice president now owns 13,471 shares of the company's stock, valued at $2,229,719.92. This represents a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.57% of the company's stock.

Institutional Trading of Clorox

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prospera Private Wealth LLC bought a new position in Clorox during the third quarter worth about $27,000. Innealta Capital LLC bought a new position in shares of Clorox during the second quarter worth $30,000. Trifecta Capital Advisors LLC grew its holdings in shares of Clorox by 139.8% in the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company's stock valued at $30,000 after buying an additional 130 shares during the period. First Foundation Advisors bought a new position in shares of Clorox during the 1st quarter valued at about $31,000. Finally, Family Firm Inc. acquired a new position in shares of Clorox in the second quarter valued at approximately $31,000. 78.53% of the stock is owned by institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.